Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02061540 · ClinicalTrials.gov registry record · Phase 2
Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis
A Phase 2 study, sponsored by Mirum Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT02061540 is a Phase 2 study that has completed, run by Mirum Pharmaceuticals. The registered enrollment target is 27 participants.
The verdict
NCT02061540, a Phase 2 study, has completed, sponsored by Mirum Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
The study is an open-label study in adults with primary sclerosing cholangitis to evaluate the safety, tolerability, and effect of 14-weeks of daily dosing of LUM001.
Interventions
- DRUG LUM001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2014-03 |
| Est. Completion | 2016-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02061540
The ClinicalTrials.gov registry entry for NCT02061540 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mirum Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LUM001 is the first listed.
NCT02061540 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02061540 about?
NCT02061540 is a clinical study titled "Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis". The study is an open-label study in adults with primary sclerosing cholangitis to evaluate the safety, tolerability, and effect of 14-weeks of daily dosing of LUM001.
What is the current status of trial NCT02061540?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2014-03. Estimated completion is 2016-02.
What interventions are being tested in trial NCT02061540?
The interventions under investigation include: LUM001 (DRUG).
Who is sponsoring clinical trial NCT02061540?
This trial is sponsored by Mirum Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.